Aytu BioPharma Inc (AYTU)
1.54
-0.20
(-11.75%)
USD |
NASDAQ |
Nov 14, 16:00
1.54
0.00 (0.00%)
After-Hours: 19:56
Aytu BioPharma Gross Profit Margin (Quarterly): 66.23% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 66.23% |
| March 31, 2024 | 64.99% |
| December 31, 2023 | 70.65% |
| September 30, 2023 | 66.90% |
| June 30, 2023 | 60.41% |
| March 31, 2023 | 56.06% |
| December 31, 2022 | 65.81% |
| September 30, 2022 | 65.20% |
| June 30, 2022 | 54.07% |
| March 31, 2022 | 52.42% |
| December 31, 2021 | 53.18% |
| September 30, 2021 | 56.88% |
| June 30, 2021 | 48.12% |
| March 31, 2021 | -3.35% |
| December 31, 2020 | 58.73% |
| September 30, 2020 | 69.95% |
| June 30, 2020 | 64.33% |
| March 31, 2020 | 75.50% |
| Date | Value |
|---|---|
| December 31, 2019 | 80.91% |
| September 30, 2019 | 73.91% |
| June 30, 2019 | 62.17% |
| March 31, 2019 | 74.06% |
| December 31, 2018 | 70.74% |
| September 30, 2018 | 71.30% |
| June 30, 2018 | 73.94% |
| March 31, 2018 | -87.29% |
| December 31, 2017 | 63.33% |
| September 30, 2017 | 73.31% |
| June 30, 2017 | 58.17% |
| March 31, 2017 | 63.71% |
| December 31, 2016 | 30.57% |
| September 30, 2016 | 72.50% |
| June 30, 2016 | 64.28% |
| March 31, 2016 | 49.02% |
| December 31, 2015 | 48.00% |
| September 30, 2015 | 92.34% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-3.35%
Minimum
Mar 2021
80.91%
Maximum
Dec 2019
59.32%
Average
64.33%
Median
Jun 2020
Gross Profit Margin (Quarterly) Benchmarks
| enVVeno Medical Corp | -- |
| Bristol-Myers Squibb Co | 75.13% |
| Telesis Bio Inc | -51.55% |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 84.00% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -48.64% |
| Return on Assets | -12.23% |
| Return on Invested Capital | -32.57% |
| Profit Margin (Quarterly) | -25.68% |
| Operating Margin (Quarterly) | -8.51% |
| Return on Net Operating Assets | -15.85% |